Oral semaglutide: Phase I data

Novo Nordisk disclosed in its 2Q13 earnings that data from 5 Phase I trials in 400 healthy volunteers and 10 Type II diabetics showed that oral semaglutide was well tolerated. In a 10-week Phase I tri...